問卷

TPIDB > Principal Investigator

Principal Investigator


Tao-Yuan General Hospital Minisity of Health and Welfare (在職)

Division of General Internal Medicine

Division of Infectious Disease

Taipei Medical University Hospital (在職)

Division of Infectious Disease

更新時間:2023-09-19

林宜君
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

15Cases

2021-09-01 - 2023-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2022-07-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-12-15 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2022-10-27 - 2030-01-21

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2024-01-01 - 2025-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-05-03 - 2023-12-28

Phase III

Completed
A Multicenter Study to Evaluate Long-term Safety and Tolerability of Open Label Sacubitril/Valsartan in Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed Study CLCZ696B2319
  • Condition/Disease

    Heart failure

  • Test Drug

    健安心/Entresto (LCZ696)

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2025-11-14 - 2030-06-28

Phase III

Active
A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age with heart failure (HF) and left ventricular systolic dysfunction (LVSD)
  • Condition/Disease

    Left Ventricular Systolic Dysfunction

  • Test Drug

    錠劑 錠劑 錠劑 懸浮液用顆粒劑 錠劑 懸液用顆粒劑

Participate Sites
6Sites

Recruiting6Sites

2026-02-20 - 2031-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2020-06-01 - 2022-12-31

Phase I

A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
  • Condition/Disease

    Anti-infectives for systemic use

  • Test Drug

    UB-421 SC (dB4C7C22-6 mAb)

Participate Sites
3Sites

Recruiting3Sites

1 2